Drugs / Aplindore
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00834327 | Feb → Nov 2009 | restless legs syndrome | Neurogen Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00809302 | Dec 2008 → Aug 2009 | Parkinson disease | Neurogen Corporation | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00626418 Comparator | Feb → Oct 2008 | restless legs syndrome | Ligand Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00623324 Comparator | Jan → Jul 2008 | Parkinson disease | Ligand Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aplindore | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00623324 ↗ |
| Known as | Aplindor | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110659 ↗ |
| Known as | APLINDORE FUMARATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110659 ↗ |
| Known as | DAB-452 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110659 ↗ |
| Known as | Palindore | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110659 ↗ |
| Known as | Palindore fumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110659 ↗ |
| Action | Activate | “partial agonist of the D2 dopamine receptor” NCT00626418 ↗1“Dopamine D2 receptor partial agonist” CHEMBL2110659 ↗ |
| Modality | Small molecule | “Aplindore is an orally available, small molecule partial agonist of the D2 dopamine receptor.” NCT00626418 ↗ |
| Route | Oral | “orally available” NCT00626418 ↗ |
| Target | DRD2 | “Dopamine D2 receptor partial agonist” CHEMBL2110659 ↗ |